This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

  1. Article
  2. Source: Campus Sanofi
  3. 22 May 2024
6 min

A Real World Case Study: Presented by Dr Sarah Lawless

Author: Dr Sarah Lawless

Consultant Haematologist, Belfast City Hospital

  

Prescribing Information for SARCLISA®▼ (isatuximab) can be found via the Product Card at the bottom of the page.

In this video, you'll learn about

A case study presented by Dr Sarah Lawless of an 81 year old RRMM patient who receives SARCLISA® + Pd at 4th Line. The case study demonstrates that elderly patients can tolerate triplet-based therapy and that egh Isa Pd should be considered for all eligible patients at 4th line.

Learn more about SARCLISA®

Overview of SARCLISA®

Find out more about SARCLISA® + Pd efficacy and safety data and dosing information.

Dosing and Administration Guide

Download a handy guide to SARCLISA dosing and administration information

Patient Booklet

Download SARCLISA® patient information.

1/3

Overview of SARCLISA®

Find out more about SARCLISA® + Pd efficacy and safety data and dosing information.

Dosing and Administration Guide

Download a handy guide to SARCLISA dosing and administration information

Patient Booklet

Download SARCLISA® patient information.


 

Get in touch with
the Oncology Team

Relapsed Refractory
Multiple Myeloma Product

Learn more  →

Prescribing information UK

MAT-XU-2202578 (v5.0)
Date of preparation: January 2025

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

MAT-XU-2402045 (v2.0) Date of Preparation: January 2025